> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md). # Non-Small Cell Lung Cancer NSCLC is an early but increasingly interesting setting for WFA. The strongest reasons are EMT suppression, paclitaxel synergy, and immune checkpoint sensitisation. ### Cell data WFA suppresses `TGFβ1` and `TNFα`-driven EMT in NSCLC cell lines such as `A549` and `H1299`. At sub-cytotoxic concentrations, it reduces adhesion, migration, and invasion without needing overt cell killing. That makes the anti-metastatic signal especially interesting. WFA has also shown synergy with paclitaxel in NSCLC models, improving effects on proliferation and invasive behaviour. ### Animal data The most important animal data comes from syngeneic lung cancer work. In that setting, WFA combined with anti-PD-L1 therapy reduced tumour growth more effectively than either agent alone and increased `CD8+` T-cell infiltration. This makes NSCLC the strongest current disease setting for WFA's checkpoint-sensitisation hypothesis. ### Human data There is no NSCLC-specific human efficacy trial yet. ### Clinical setting assessment NSCLC remains early, but the translational logic is strong. Because checkpoint inhibitors are already part of standard care in many lung cancer settings, WFA fits a clinically recognisable design space. That makes this disease area more interesting than its current evidence volume alone might suggest. ### Bottom line NSCLC is not yet one of the deepest WFA evidence bases, but it may be one of the most strategically important for future combination trials. ### Key references Kim S. H. et al. — EMT suppression and anti-invasive effects in NSCLC models.\ Banerjee S. et al. — anti-PD-L1 sensitisation and immune-microenvironment reshaping in syngeneic lung cancer.\ Access and availability:\ Source: MCS Formulas, “Withaferin A Pro Liposomal.”\ `50 mg` WFA per capsule. Available via healthcare professional request.\ ### In this section #### Core pages * [Withaferin A (WFA) in Oncology](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology.md) * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/anti-cancer-mechanisms.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/immune-effects.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md) #### Cancer-type pages * [WFA Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type.md) * [Breast Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/breast-cancer.md) * [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/ovarian-cancer.md) * [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md) * [Glioblastoma](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/glioblastoma.md) * [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/other-cancer-types.md) #### Practical pages * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/pharmacokinetics-and-metabolism.md) * [Sourcing Quality](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/sourcing-quality.md) * [Safety, Interactions and WFA Dosing](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md) * [Hormones — ER-α and Androgens](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/hormones-er-a-and-androgens.md) * [Terrain Support — Liposomal WFA vs Whole-Plant Ashwagandha](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/terrain-support-liposomal-wfa-vs-whole-plant-ashwagandha.md) {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.